Tag: Bayer

The Supreme Court’s 7–2 ruling excising thousands of Roundup claims from Bayer’s docket was the kind of event that sends ...

Bayer’s stock crept back above a closely watched technical threshold on Friday, but the real drama for the German healthcare ...

Two legal milestones are converging on Bayer within weeks, and the market is holding its breath. By the end of ...

Bayer shares vaulted 4.6% to €37.51 on Thursday, hitting a monthly high as investors placed their bets on a single ...

Bayer is attempting to write a new chapter, one built on clinical proof rather than corporate promises. The German conglomerate's ...

Bayer shares entered the week walking a tightrope just above a key long-term trendline, but the company’s pipeline and digital ...

Bayer’s stock is caught in a familiar squeeze: strong operational performance and promising drug data are consistently overshadowed by the ...

Bayer delivered a first-quarter earnings report that should have been a catalyst for its stock. Adjusted earnings per share jumped ...

Bayer’s annual general meeting on April 24 was a study in contradictions. Major institutional investors praised CEO Bill Anderson’s restructuring ...

Bayer enters a defining week with its stock under pressure, a Supreme Court hearing on the horizon, and shareholders having ...